Table I.
Acute myeloid leukemia chemotherapy regimens.
| Regimen | Dosing | |
|---|---|---|
| High-risk patients | ||
| Induction therapy | Cycle 1 | |
| Cytarabine | Days 1–7: | Cytarabine 100 mg/m2/day continuous intravenous (IV) infusion for 2 h |
| Daunorubicin | Days 1, 3 and 5: | Daunorubicin 30 mg/m2/day continuous IV infusion for 1 h |
| Etoposide | Days 1–5: | Etoposide 100 mg/m2/day IV for 3 h |
| Mitoxantrone | Day 2: | Intrathecal (IT) chemotherapy (Table II) |
| Cycle 2 | ||
| Days 1–7: | Cytarabine 100 mg/m2/day continuous IV infusion for 2 h | |
| Days 1, 3. 5: | Daunorubicin 30 mg/m2/day continuous IV infusion for 1 h | |
| Days 1–5: | Etoposide 100 mg/m2/day continuous IV infusion for 3 h | |
| Day 2: | IT chemotherapy (Table II) | |
| Cycle 3 | ||
| Days 1–5: | Cytarabine 100 mg/m2/day continuous IV infusion for 2 h | |
| Days 1–3: | Mitoxantrone 10 mg/m2/day continuous IV infusion for 30 min | |
| Day 2: | Intrathecal (IT) chemotherapy (Table II) | |
| Maintenance therapy | Cycle 1 | |
| Cytarabine | Days 1–3: | Cytarabine 1 g/m2/day continuous IV infusion for 2 h |
| Daunorubicin | Days 1–3: | Mitoxantrone 10 mg/m2/day continuous IV infusion for 30 min |
| Etoposide | Day 2: | Intrathecal (IT) chemotherapy (Table II) |
| Mitoxantrone | Cycle 2 | |
| Days 1–3: | Cytarabine 2 g/m2/day continuous IV infusion for 2 h | |
| Days 1–4: | Etoposide 100 mg/m2/day continuous IV infusion for 1 h | |
| Day 2: | Intrathecal (IT) chemotherapy (Table II) | |
| Cycle 3 | ||
| Days 1–3: | Cytarabine 3 g/m2/day continuous IV infusion for 2 h | |
| Cycle 4 | ||
| Days 1–3: | Cytarabine 2 g/m2/day continuous IV infusion for 2 h | |
| Days 1–4: | Etoposide 100 mg/m2/day continuous IV infusion for 1 h | |
| Day 2: | Intrathecal (IT) chemotherapy (Table II) | |
| Low-risk patients | ||
| Induction therapy | Cycle 1 | |
| Cytarabine | Days 1–7: | Cytarabine 100 mg/m2/day continuous intravenous (IV) infusion for 2 h |
| Daunorubicin | Days 1, 3 and 5: | Daunorubicin 30 mg/m2/day continuous IV infusion for 1 h |
| Etoposide | Days 1–5: | Etoposide 100 mg/m2/day IV for 3 h |
| Day 2: | Intrathecal (IT) chemotherapy (Table II) | |
| Cycle 2 | ||
| Days 1–7: | Cytarabine 100 mg/m2/day continuous IV infusion for 2 h | |
| Days 1, 3 and 5: | Daunorubicin 30 mg/m2/day continuous IV infusion for 1 h | |
| Days 1–5: | Etoposide 100 mg/m2/day continuous IV infusion for 3 h | |
| Maintenance therapy | Cycle 1 | |
| Cytarabine | Days 1–3: | Cytarabine 1 g/m2/day continuous IV infusion for 2 h |
| Daunorubicin | Days 1–3: | Daunorubicin 25 mg/m2/day continuous IV infusion for 1 h |
| Etoposide | Cycle 2 | |
| Days 1–3: | Cytarabine 1 g/m2/day continuous IV infusion for 2 h | |
| Days 1–4: | Etoposide 100 mg/m2/day continuous IV infusion for 1 h | |
| Cycle 3 | ||
| Days 1–3: | Cytarabine 2 g/m2/day continuous IV infusion for 2 h | |
| Cycle 4 | ||
| Days 1–3: | Cytarabine 1 g/m2/day continuous IV infusion for 2 h | |
| Days 1–4: | Etoposide 100 mg/m2/day continuous IV infusion for 1 h |